

# Research Compliance Activity and Turn-Around-Time (TAT) Summary Report

Fiscal Year 2024 (7/1/2023 to 6/30/2024)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Human Subjects Office/Institutional Review Board (IRB)									
	AAHRPP Median TAT*	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
		Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board									
New Studies - Full Board (to IRB review)	14.0	10.0	9.0						
New Studies - Full Board (to IRB approval)	42.0	44.0	22.5						
Expedited									
New Studies - Expedited (to IRB review)	6.0	6.0	7.0						
New Studies - Expedited (to IRB approval)	18.0	22.0	14.5						
Exempt									
New Studies - Exempt (to determination)	10.0	13.0	9.0						
Amendments									
Amendments (to IRB approval)	n/a	5.0	1.0						

\*Source: AAHRPP "2022 Metrics on Human Research Protection Program Performance" updated July 2023

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	31	42	11									
New Studies - Expedited	147	132	-15 (10.2%)									
New Studies - Exempt	445	414	-31 (7.0%)									
Amendments	1309	1284	-25 (1.9%)									
Closeouts	248	244	-4 (1.6%)									
Continuing Reviews	176	191	15									
Reliance Submissions	507	495	-12 (2.4%)									
General Information (FYI)	76	64	-12 (15.8%)									
Not Human Subjects Research Determinations	72	67	-5 (6.9%)									
<b>TOTAL</b>	<b>3011</b>	<b>2933</b>	<b>-78 (2.6%)</b>	<b>0</b>	<b>0</b>		<b>0</b>	<b>0</b>		<b>0</b>	<b>0</b>	

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	15				15